Phase 3 N=2,518 Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit
Nosocomial Infections
Primary: Bacteremia — 3.52; 4.93 events per 1000 at-risk days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=715 A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy
Hypogonadism
Primary: Number of Participants With Total Serum Testosterone Concentration Within Normal Range at Week 12 — 43; 217 participants — p=<0.001
Phase 3 N=18,144 IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
Hypercholesterolemia · Myocardial Infarction
Primary: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a…
Phase 3 N=280 Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
HER2/Neu Positive · Stage IA Breast Cancer · Stage IB Breast Cancer
Primary: pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy — 56.5; 54.2 percentage of…
Phase 3 N=905 Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-C at Week 52 — 6.83; -50.14 percent change — p=<0.001
Phase 3 N=42 Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea
Diarrhea
Primary: Percentage of Patients Having Minimum Reduction of 50% or Normalization (≤3 Stools/24hours) in the Mean Number of Stools (Mean of Last 7 Days) — 44.4; 55.6 Percentage of…
Phase 3 N=100 A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years
Healthy Japanese Children Age 2 Years Through 6 Years
Primary: Number of Participants With Solicited Symptoms Experienced From Administration of MEDI3250 — 57 subjects
Phase 3 N=61 Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds
Burns
Primary: Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care — 85.7 percentage of…
Phase 3 N=177 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth
Diphtheria · Tetanus · Whooping Cough
Primary: Percentage of Participants With Seroprotection After Vaccinations With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Following a Documented Dose of a Commercial…
Phase 3 N=1,015 Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
Chemotherapy-Induced Nausea and Vomiting (CINV)
Primary: Percentage of Participants With Complete Response From 25 to 120 Hours After Initiation of Moderately Emetogenic Chemotherapy (MEC) — 78.9; 68.5 Percentage of…
Phase 3 N=230 Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients
Hepatocellular Carcinoma
Primary: Recurrence Free Survival(RFS) — 44.0; 30.0 months — p=0.01
Phase 3 N=104 Comparison of Two Methods of Securing Skin Grafts Using Negative Pressure Wound Therapy: Vacuum Assisted Closure (VAC) and Gauze Suction (GSUC)
Wound Healing
Primary: Percentage of Wounds With Complete Skin Graft Take — 80; 78 percentage of wounds — p=0.80
Phase 3 N=1,306 Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
Chronic Plaque Psoriasis
Primary: Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index)…
Phase 3 N=668 UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
Multiple Myeloma
Primary: Overall Survival — 65; 58 percentage of participants
Phase 3 N=879 A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Subjects in Sustained Remission at Week 52 — 15.0; 28.9 percentage of subjects — p=<0.001